ResMed Inc. vs Under Armour Inc Class A — how do they compare? ResMed Inc. trades at $225.38 (market cap $32.61B), while Under Armour Inc Class A trades at $5.28 (market cap $2.26B). The key difference: ResMed Inc. is far larger — about 14.4× Under Armour Inc Class A's market cap, and ResMed Inc. pays a 1.17% dividend while Under Armour Inc Class A pays none. Which is the better fit depends on your goals.
| RMD | UAA | |
|---|---|---|
Market Cap | $32.61B | $2.26B |
Sector | Health | Consumer Cyclical |
52-Week High | $293.73 | $8.14 |
52-Week Low | $182.82 | $4.17 |
Enterprise Value | $31.97B | $3.24B |
Dividend Yield | 1.17% | — |
Signals from Pluang's Aura AI — not financial advice
ResMed (RMD) trades at $221.22, up 0.53% with a bullish technical signal and strong fundamental performance. The company delivered four consecutive quarterly earnings beats, with Q4 2026 EPS of $2.95 beating expectations by 2.1%. Revenue grew 9% year-over-year to $1.5 billion, while maintaining robust profitability with 61.1% gross margins and 26.9% net income margins. Recent strategic moves include the $490 million sale of MatrixCare to focus on core sleep and respiratory care markets.
The stock presents a compelling growth story with consistent execution, though near-term headwinds from weak 2027 revenue guidance create uncertainty. Analyst consensus targets $235.00 (6.2% upside) with 40% buy ratings. Key risks include ventilator sales suspension, cost pressures, and competitive threats in the medical device space. The company's strong cash flow generation and shareholder returns ($1.0 billion in 2026) support long-term value creation.
Under Armour (UAA) is trading at $5.265, down 10.15% with bearish technical signals despite recent earnings beats. The company faces significant fundamental challenges with negative net income margins (-9.99%) and declining revenue trends from $5.7B in 2024 to $5.2B in 2025. Recent Q1 2027 earnings showed a profit beat but weaker revenue and cautious guidance, reflecting ongoing struggles in North American and Asia-Pacific markets. Cash flow remains negative at -$362M for 2025, though valuation ratios like P/S of 0.46 appear attractive relative to peers.
The outlook remains challenging with persistent revenue declines and profitability issues offset by potential value opportunities. Key risks include weak consumer spending, inventory management challenges, and competitive pressures. Analyst consensus is mixed with 27% buy ratings but a $6.67 price target suggesting 27% upside from current levels, though institutional sentiment appears cautious given the technical bearish signals and fundamental headwinds.
Trailing returns across standard periods
Latest headlines on both assets
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →Under Armour develops, markets, and distributes athletic apparel, footwear, and accessories in North America and other territories. Consumers of its apparel include professional and amateur athletes, sponsored college and professional teams, and people with active lifestyles. The company sells merchandise through direct-to-consumer, including e-commerce and more than 400 combined factory house and brand house stores, and wholesale channels. Under Armour also operates a digital fitness app called MapMyFitness. The Baltimore-based company was founded in 1996.
Read more on UAA →